iNKT cell-activating immunotherapy (RIKEN)

N/A

Report date: 2022/09/06 18:03:16

Base Information

Drug NameiNKT cell-activating immunotherapy (RIKEN)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionNatural killer cells modulators

TargetsNot applicable

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesInstitute Physical Chemical Research (Riken)

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesInstitute Physical Chemical Research (Riken)

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A